{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:12:59Z","timestamp":1788225179229,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101362","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:06:14Z","timestamp":1769792774000},"page":"101362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bystander or perpetrator: Unravelling the significance and challenges of MGUS"],"prefix":"10.1016","volume":"76","author":[{"given":"Malini","family":"Surapaneni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Edmisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101362_bb0005","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, Multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.blre.2026.101362_bb0020","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archinte.1975.00330010097013","article-title":"Idiopathic (asymptomatic) monoclonal gammopathies","volume":"135","author":"Ritzmann","year":"1975","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.blre.2026.101362_bb0030","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101362_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2023-186397","article-title":"The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the Istopmm study","volume":"142","author":"R\u00f6gnvaldsson","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0055","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101362_bb0060","series-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968"},{"issue":"13","key":"10.1016\/j.blre.2026.101362_bb0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2026.101362_bb0070","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/jamainternmed.2023.3798","article-title":"Estimated lifetime gained with cancer screening tests: a meta-analysis of randomized clinical trials","volume":"183","author":"Bretthauer","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.2024025415","article-title":"Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection","volume":"145","author":"Visram","year":"2025","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101362_bb0080","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2022.40.16_suppl.8045","article-title":"African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients","volume":"40","author":"Akhlaghi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101362_bb0090","series-title":"Holland-Frei cancer medicine","article-title":"Key criteria in the decision to screen","author":"Smith","year":"2003"},{"issue":"12","key":"10.1016\/j.blre.2026.101362_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2026.101362_bb0100","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0105","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/jalm\/jfaa093","article-title":"Free light chain assay drift: potential for misdiagnosis?","volume":"5","author":"Murray","year":"2020","journal-title":"J Appl Lab Med"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ajcp\/aqw099","article-title":"Serum free light chain assay and \u03ba\/\u03bb ratio performance in patients without monoclonal gammopathies:high false-positive rate","volume":"146","author":"Singh","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jalm\/jfad027","article-title":"Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance","volume":"8","author":"Rozenova","year":"2023","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/cmmr103","article-title":"Screening for light chain monoclonal gammopathy of undetermined significance_ pseudo epidemic based on current diagnostic criteria","volume":"3","author":"Singh","year":"2025","journal-title":"Cell Mol Med Res"},{"issue":"7","key":"10.1016\/j.blre.2026.101362_bb0125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamaoncol.2025.1285","article-title":"New definition of light chain monoclonal gammopathy of undetermined significance","volume":"11","author":"Einarsson Long","year":"2025","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0130","first-page":"532","article-title":"Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate","volume":"110","author":"Shpitzer","year":"2025","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.blre.2026.101362_bb0135","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2026.101362_bb0140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2026.101362_bb0145","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-018-3305-x","article-title":"Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis","volume":"97","author":"Pelzer","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1365-2141.2003.04329.x","article-title":"Bone marrow biopsy morbidity and mortality","volume":"121","author":"Bain","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000710","article-title":"This is going to hurt: revisiting the patient experience of bone marrow biopsies","volume":"6","author":"Hibbs","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-6576.2008.01874.x","article-title":"Procedure-related pain among adult patients with hematologic malignancies","volume":"53","author":"Lid\u00e9n","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0165","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3892\/etm.2022.11461","article-title":"Understanding the harm of low-dose computed tomography radiation to the body (review)","volume":"24","author":"Shi","year":"2022","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11547-015-0573-6","article-title":"Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM)","volume":"121","author":"Cretti","year":"2016","journal-title":"Radiol Med"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0175","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M23-2540","article-title":"Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance\u202f: a cohort study nested in a clinical trial","volume":"177","author":"Eythorsson","year":"2024","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.20175","article-title":"Screening for monoclonal gammopathy of undetermined significance is contraindicated","volume":"207","author":"Singh","year":"2025","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.46989\/001c.123608","article-title":"Psychological impact in individuals with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"6","author":"Patel","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-019-0172-1","article-title":"Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma","volume":"9","author":"Maatouk","year":"2019","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.blre.2026.101362_bb0200","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.V128.22.2360.2360","article-title":"Cost effectiveness in low risk MGUS patients","volume":"128","author":"Pompa","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.70102","article-title":"Clinical utility of monoclonal gammopathy testing in the evaluation of Anemia","volume":"101","author":"Maberry","year":"2026","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0210","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.blre.2026.101362_bb0215","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0220","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0225","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101362_bb0230","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0235","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-024-01126-3","article-title":"Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance","volume":"14","author":"Zuern","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0240","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4065\/82.4.428","article-title":"Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size","volume":"82","author":"Rosi\u00f1ol","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0245","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101362_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19534","article-title":"Comparison of IMWG and PANGEA risk models predicting MGUS to multiple myeloma progression in a safety net hospital","volume":"43","author":"Chandora","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2026.101362_bb0255","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2026.101362_bb0260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2026.101362_bb0265","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"Ross","year":"2010","journal-title":"Haematologica"},{"issue":"7339","key":"10.1016\/j.blre.2026.101362_bb0270","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0275","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2026.101362_bb0280","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO-25-01733","article-title":"Genomics define malignant transformation in myeloma precursor conditions","volume":"44","author":"Maura","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2026.101362_bb0290","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2013-07-513366","article-title":"MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance","volume":"122","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101362_bb0295","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood.2025030177","article-title":"Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenstr\u00f6m macroglobulinemia","volume":"146","author":"Bagratuni","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0300","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41596-020-00437-6","article-title":"Reliable detection of somatic mutations in solid tissues by laser-capture microdissection and low-input DNA sequencing","volume":"16","author":"Ellis","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.blre.2026.101362_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101242","article-title":"From MGUS to multiple myeloma: unraveling the unknown of precursor states","volume":"68","author":"Hevroni","year":"2024","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0310","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/cancers14061430","article-title":"Biological characterization and clinical relevance of circulating tumor cells: opening the Pandora\u2019s box of multiple myeloma","volume":"14","author":"Garc\u00e9s","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.blre.2026.101362_bb0315","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020332","article-title":"Predicting the progression from asymptomatic to symptomatic multiple myeloma and stage classification using gene expression data","volume":"17","author":"Karathanasis","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.blre.2026.101362_bb0325","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and management of monoclonal gammopathy of undetermined significance: a review","volume":"185","author":"Liu","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.blre.2026.101362_bb0335","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","article-title":"Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study","volume":"108","author":"Sigurbergsd\u00f3ttir","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0340","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/hematology.2020000122","article-title":"Monoclonal gammopathies of clinical significance","volume":"2020","author":"Dispenzieri","year":"2020","journal-title":"Hematology"},{"issue":"14","key":"10.1016\/j.blre.2026.101362_bb0345","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0350","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2026.101362_bb0355","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0360","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0365","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00277-014-2294-7","article-title":"IgM MGUS associated with anti-MAG neuropathy: a single institution experience","volume":"94","author":"Talamo","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0370","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11899-024-00745-8","article-title":"Monoclonal gammopathy-associated neuropathy","volume":"20","author":"Sarosiek","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0375","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal gammopathy\u2013associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0380","first-page":"99","article-title":"Peripheral neuropathy and paraproteinemia: an immunohistochemical and serologic study","volume":"4","author":"Johansen","year":"1985","journal-title":"Clin Neuropathol"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0385","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11914-018-0479-z","article-title":"Contributions of the bone microenvironment to monoclonal gammopathy of undetermined significance pathogenesis","volume":"16","author":"G\u00e1mez","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0390","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"15","key":"10.1016\/j.blre.2026.101362_bb0395","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0400","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.blre.2026.101362_bb0405","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/bloodadvances.2017010454","article-title":"Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study","volume":"1","author":"Thorsteinsdottir","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0410","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2013-05-505776","article-title":"Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"123","author":"Farr","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101362_bb0415","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0420","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101362_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876271","article-title":"Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance","volume":"13","author":"Sigurbergsd\u00f3ttir","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0430","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjh.19957","article-title":"Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: results from iStopMM, a prospective population-based screening study","volume":"206","author":"R\u00f6gnvaldsson","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0435","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12882-024-03458-5","article-title":"Systematic review and meta-analysis of the clinical features of MGRS","volume":"25","author":"Du","year":"2024","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1016\/j.blre.2026.101362_bb0440","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/j.1600-6143.2011.03643.x","article-title":"Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy","volume":"11","author":"Debiec","year":"2011","journal-title":"Am J Transplant"},{"issue":"23","key":"10.1016\/j.blre.2026.101362_bb0445","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2026.101362_bb0450","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood.V120.21.5045.5045","article-title":"A prospective, randomized, chemoprevention trial of celecoxib for high risk monoclonal gammopathy of undetermined significance and asymptomatic multiple myeloma","volume":"120","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2026.101362_bb0455","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","article-title":"The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker","volume":"15","author":"Golombick","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2026.101362_bb0460","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.23159","article-title":"Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study","volume":"87","author":"Golombick","year":"2012","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101362_bb0465","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood-2021-151878","article-title":"A randomized placebo-controlled phase 2 study of metformin for the prevention of progression of monoclonal gammopathy of undetermined significance and low risk Smoldering multiple myeloma","volume":"138","author":"Marinac","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0470","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/bloodadvances.2023011608","article-title":"Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population","volume":"8","author":"Joseph","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2026.101362_bb0475","article-title":"Dietary pattern and risk of multiple myeloma in two large prospective US cohort studies","volume":"3","author":"Lee","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"22","key":"10.1016\/j.blre.2026.101362_bb0480","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V128.22.3257.3257","article-title":"Dietary pattern and risk of monoclonal gammopathy of undetermined significance: a population-based study","volume":"128","author":"Thordardottir","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0485","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.cell.2016.10.020","article-title":"Linking the human gut microbiome to inflammatory cytokine production capacity","volume":"167","author":"Schirmer","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2026.101362_bb0490","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.47.3.397","article-title":"Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease","volume":"47","author":"Segain","year":"2000","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.blre.2026.101362_bb0495","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41598-018-37246-7","article-title":"Effects of oral butyrate supplementation on inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese males","volume":"9","author":"Cleophas","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.blre.2026.101362_bb0500","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.blre.2026.101362_bb0505","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.blre.2026.101362_bb0510","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","article-title":"E3A06: randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma","volume":"37","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101362_bb0515","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101362_bb0520","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2021-149797","article-title":"A phase II study of daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma","volume":"138","author":"Nadeem","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101362_bb0525","year":"2026"},{"key":"10.1016\/j.blre.2026.101362_bb0530","doi-asserted-by":"crossref","DOI":"10.2196\/51368","article-title":"Design and rationale of prolonged nightly fasting for multiple myeloma prevention (PROFAST): protocol for a randomized controlled pilot trial","volume":"13","author":"Lee","year":"2024","journal-title":"JMIR Res Protoc"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101362_bb0535","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1182\/blood-2021-151049","article-title":"A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the nutrition prevention (NUTRIVENTION) study","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101362_bb0540","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1182\/blood-2022-159794","volume":"140","author":"Shah","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101362_bb0545","series-title":"Curcumin and piperine in patients on surveillance for monoclonal gammopathy, smoldering myeloma or prostate cancer","author":"Lipe","year":"2026"},{"key":"10.1016\/j.blre.2026.101362_bb0550","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood-2021-151878","article-title":"A randomized placebo-controlled phase 2 study of metformin for the prevention of progression of monoclonal gammopathy of undetermined significance and low risk smoldering multiple myeloma","volume":"138","author":"Marinac","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101362_bb0555","series-title":"Rifaximin in patients with monoclonal gammopathy","year":"2026"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:13:18Z","timestamp":1788221598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":111,"alternative-id":["S0268960X26000019"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101362","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bystander or perpetrator: Unravelling the significance and challenges of MGUS","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101362"}}